NEWTON, Mass.--(BUSINESS WIRE)--April 24, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Food and Drug Administration (FDA) accepted Novelos’ Investigational New Drug Application (IND) for NOV-205, its second clinical stage compound. The initial U.S.-based Phase 1b trial will evaluate NOV-205 as monotherapy for chronic hepatitis C genotype 1 patients who have failed pegylated interferon plus ribavirin therapy.
